These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27238930)

  • 21. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
    Wang AY; Hou SK; Li SJ; Kao WF
    Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
    [No Abstract]   [Full Text] [Related]  

  • 22. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
    Danford C; Chan P; Magill SB
    WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis.
    Dizon S; Keely EJ; Malcolm J; Arnaout A
    Can J Diabetes; 2017 Oct; 41(5):499-503. PubMed ID: 28797889
    [No Abstract]   [Full Text] [Related]  

  • 24. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
    Ahmed M; McKenna MJ; Crowley RK
    Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes Drug Receives New Indication.
    Aschenbrenner DS
    Am J Nurs; 2017 Apr; 117(4):24-25. PubMed ID: 28333738
    [No Abstract]   [Full Text] [Related]  

  • 26. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
    [No Abstract]   [Full Text] [Related]  

  • 28. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
    Qiu H; Novikov A; Vallon V
    Diabetes Metab Res Rev; 2017 Jul; 33(5):. PubMed ID: 28099783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
    Rashid O; Farooq S; Kiran Z; Islam N
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27177938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gliflozins: ketoacidosis.
    Prescrire Int; 2016 Mar; 25(169):68. PubMed ID: 27152399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.
    Ogawa W; Sakaguchi K
    J Diabetes Investig; 2016 Mar; 7(2):135-8. PubMed ID: 27042263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases.
    Venkatesh B; Moore G; Gill D; Kelly W
    Crit Care Resusc; 2015 Dec; 17(4):280-2. PubMed ID: 26640065
    [No Abstract]   [Full Text] [Related]  

  • 34. Non-occlusive Mesenteric Ischemia with Diabetic Ketoacidosis and Lactic Acidosis Following the Administration of a Sodium Glucose Co-transporter 2 Inhibitor.
    Gocho N; Aoki E; Okada C; Omura K; Hirashima T; Suzuki N; Tanaka H; Omori Y
    Intern Med; 2016; 55(13):1755-60. PubMed ID: 27374678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

  • 36. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
    Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
    Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
    Messana JA; Schwartz SS; Townsend RR
    Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
    Bonora BM; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant.
    Finucane FM
    Med Hypotheses; 2018 May; 114():11-12. PubMed ID: 29602453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canagliflozin induced diabetic ketoacidosis.
    Diéguez-Felechosa M; Suárez-Gutiérrez L
    Endocrinol Nutr; 2016 Oct; 63(8):430-1. PubMed ID: 27346596
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.